# newdoc id = AMALGUM_academic_cyclic
# sent_id = AMALGUM_academic_cyclic-1
# s_type = frag
# text = 1. Introduction
1	1.	1.	X	LS	_	2	dep	2:dep	Discourse=preparation:1->4
2	Introduction	introduction	NOUN	NN	Number=Sing	0	root	0:root	Entity=(abstract-1)

# sent_id = AMALGUM_academic_cyclic-2
# s_type = decl
# text = Proteases are associated with many signaling biological pathways, and it is has been proven that the number of diseases like cancer, HIV, infectious diseases, and diabetes are treated by inhibiting proteases.
1	Proteases	protease	NOUN	NNS	Number=Plur	3	nsubj:pass	3:nsubj:pass	Discourse=preparation:2->4|Entity=(abstract-2)
2	are	be	AUX	VBP	Mood=Ind|Number=Plur|Person=3|Tense=Pres|VerbForm=Fin	3	aux:pass	3:aux:pass	_
3	associated	associate	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root	_
4	with	with	ADP	IN	_	8	case	8:case	_
5	many	many	ADJ	JJ	Degree=Pos	8	amod	8:amod	Entity=(abstract-3
6	signaling	signal	VERB	VBG	VerbForm=Ger	8	amod	8:amod	_
7	biological	biological	ADJ	JJ	Degree=Pos	8	amod	8:amod	_
8	pathways	pathway	NOUN	NNS	Number=Plur	3	obl	3:obl:with	Entity=abstract-3)|SpaceAfter=No
9	,	,	PUNCT	,	_	15	punct	15:punct	_
10	and	and	CCONJ	CC	_	15	cc	15:cc	Discourse=attribution:3->4
11	it	it	PRON	PRP	Case=Acc|Gender=Neut|Number=Sing|Person=3|PronType=Prs	15	expl	15:expl	Entity=(abstract-1)
12	is	be	AUX	VBZ	Mood=Ind|Number=Sing|Person=3|Tense=Pres|VerbForm=Fin	15	aux:pass	15:aux:pass	_
13	has	have	AUX	VBZ	Mood=Ind|Number=Sing|Person=3|Tense=Pres|VerbForm=Fin	15	aux	15:aux	_
14	been	be	AUX	VBN	Tense=Past|VerbForm=Part	15	aux:pass	15:aux:pass	_
15	proven	prove	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	3	conj	3:conj:and	_
16	that	that	SCONJ	IN	_	32	mark	32:mark	Discourse=ROOT:4
17	the	the	DET	DT	Definite=Def|PronType=Art	18	det	18:det	Entity=(abstract-4
18	number	number	NOUN	NN	Number=Sing	32	nsubj:pass	32:nsubj:pass	_
19	of	of	ADP	IN	_	20	case	20:case	_
20	diseases	disease	NOUN	NNS	Number=Plur	18	nmod	18:nmod:of	Entity=(abstract-5
21	like	like	ADP	IN	_	22	case	22:case	_
22	cancer	cancer	NOUN	NN	Number=Sing	20	nmod	20:nmod:like	Entity=(abstract-6)|SpaceAfter=No
23	,	,	PUNCT	,	_	24	punct	24:punct	_
24	HIV	HIV	NOUN	NN	Abbr=Yes|Number=Sing	22	conj	20:nmod:like|22:conj:and	Entity=(abstract-7)|SpaceAfter=No
25	,	,	PUNCT	,	_	27	punct	27:punct	_
26	infectious	infectious	ADJ	JJ	Degree=Pos	27	amod	27:amod	Entity=(abstract-5
27	diseases	disease	NOUN	NNS	Number=Plur	22	conj	20:nmod:like|22:conj:and	Entity=abstract-5)|SpaceAfter=No
28	,	,	PUNCT	,	_	30	punct	30:punct	_
29	and	and	CCONJ	CC	_	30	cc	30:cc	_
30	diabetes	diabet	NOUN	NN	Number=Sing	22	conj	20:nmod:like|22:conj:and	Entity=abstract-4)abstract-5)(abstract-8)
31	are	be	AUX	VBP	Mood=Ind|Number=Sing|Person=3|Tense=Pres|VerbForm=Fin	32	aux:pass	32:aux:pass	_
32	treated	treat	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	15	csubj:pass	15:csubj:pass	_
33	by	by	SCONJ	IN	_	34	mark	34:mark	Discourse=means:5->4
34	inhibiting	inhibit	VERB	VBG	VerbForm=Ger	32	advcl	32:advcl:by	_
35	proteases	protease	NOUN	NNS	Number=Plur	34	obj	34:obj	Entity=(abstract-2)|SpaceAfter=No
36	.	.	PUNCT	.	_	3	punct	3:punct	_

# sent_id = AMALGUM_academic_cyclic-3
# s_type = decl
# text = Pharmaceutical companies develop commercial drugs to inhibit aspartyl proteases, serine proteases, and cysteine proteases.
1	Pharmaceutical	Pharmaceutical	ADJ	JJ	Degree=Pos	2	amod	2:amod	Discourse=joint:6->4|Entity=(organization-9
2	companies	company	NOUN	NNS	Number=Plur	3	nsubj	3:nsubj	Entity=organization-9)
3	develop	develop	VERB	VBP	Mood=Ind|Number=Plur|Person=3|Tense=Pres|VerbForm=Fin	0	root	0:root	_
4	commercial	commercial	ADJ	JJ	Degree=Pos	5	amod	5:amod	Entity=(substance-10
5	drugs	drug	NOUN	NNS	Number=Plur	3	obj	3:obj	_
6	to	to	PART	TO	_	7	mark	7:mark	Discourse=purpose:7->6
7	inhibit	inhibit	VERB	VB	VerbForm=Inf	5	acl	5:acl:to	_
8	aspartyl	aspartyl	NOUN	NN	Number=Sing	9	compound	9:compound	Entity=(abstract-2(abstract-2(abstract-11)
9	proteases	protease	NOUN	NNS	Number=Plur	7	obj	7:obj	Entity=abstract-2)|SpaceAfter=No
10	,	,	PUNCT	,	_	12	punct	12:punct	_
11	serine	serine	NOUN	NN	Number=Sing	12	compound	12:compound	Entity=(abstract-2(animal-12)
12	proteases	protease	NOUN	NNS	Number=Plur	9	conj	7:obj|9:conj:and	Entity=abstract-2)|SpaceAfter=No
13	,	,	PUNCT	,	_	16	punct	16:punct	_
14	and	and	CCONJ	CC	_	16	cc	16:cc	_
15	cysteine	cysteine	NOUN	NN	Number=Sing	16	compound	16:compound	Entity=(abstract-2(abstract-13)
16	proteases	protease	NOUN	NNS	Number=Plur	9	conj	7:obj|9:conj:and	Entity=substance-10)abstract-2)abstract-2)|SpaceAfter=No
17	.	.	PUNCT	.	_	3	punct	3:punct	_

# sent_id = AMALGUM_academic_cyclic-4
# s_type = decl
# text = Among several protease inhibitors, serine protease inhibitors received significant interest in various applications focused mainly in therapeutics.
1	Among	among	ADP	IN	_	4	case	4:case	Discourse=joint:8->4
2	several	several	ADJ	JJ	Degree=Pos	4	amod	4:amod	Entity=(abstract-14
3	protease	protease	NOUN	NN	Number=Sing	4	compound	4:compound	Entity=(abstract-15)
4	inhibitors	inhibitor	NOUN	NNS	Number=Plur	9	obl	9:obl:among	Entity=abstract-14)|SpaceAfter=No
5	,	,	PUNCT	,	_	4	punct	4:punct	_
6	serine	serine	NOUN	NN	Number=Sing	8	compound	8:compound	Entity=(abstract-16(animal-12)
7	protease	protease	NOUN	NN	Number=Sing	8	compound	8:compound	Entity=(abstract-15)
8	inhibitors	inhibitor	NOUN	NNS	Number=Plur	9	nsubj	9:nsubj	Entity=abstract-16)
9	received	receive	VERB	VBD	Mood=Ind|Number=Plur|Person=3|Tense=Past|VerbForm=Fin	0	root	0:root	_
10	significant	significant	ADJ	JJ	Degree=Pos	11	amod	11:amod	Entity=(abstract-17
11	interest	interest	NOUN	NN	Number=Sing	9	obj	9:obj	Entity=abstract-17)
12	in	in	ADP	IN	_	14	case	14:case	_
13	various	various	ADJ	JJ	Degree=Pos	14	amod	14:amod	Entity=(abstract-18
14	applications	application	NOUN	NNS	Number=Plur	9	obl	9:obl:in	_
15	focused	focus	VERB	VBN	Tense=Past|VerbForm=Part	14	acl	14:acl	Discourse=elaboration:9->8
16	mainly	mainly	ADV	RB	Degree=Pos	15	advmod	15:advmod	_
17	in	in	ADP	IN	_	18	case	18:case	_
18	therapeutics	therapeutics	NOUN	NNS	Number=Plur	15	obl	15:obl:in	Entity=abstract-18)(abstract-19)|SpaceAfter=No
19	.	.	PUNCT	.	_	9	punct	9:punct	_

# sent_id = AMALGUM_academic_cyclic-5
# s_type = decl
# text = Serine protease inhibitors shown in Table 1, are used in treating diseases like immune-related disorders, inflammatory, respiratory, AIDS, neurodegenerative, and metabolic disorders.
1	Serine	serine	NOUN	NN	Number=Sing	2	compound	2:compound	Discourse=joint:10->4|Entity=(abstract-16(abstract-15(animal-12)
2	protease	protease	NOUN	NN	Number=Sing	3	compound	3:compound	Entity=abstract-15)
3	inhibitors	inhibitor	NOUN	NNS	Number=Plur	10	nsubj:pass	10:nsubj:pass	_
4	shown	show	VERB	VBN	Tense=Past|VerbForm=Part	3	acl	3:acl	Discourse=elaboration:11->10
5	in	in	ADP	IN	_	6	case	6:case	_
6	Table	Table	PROPN	NNP	Number=Sing	4	obl	4:obl:in	Entity=(abstract-20
7	1	1	NUM	CD	NumForm=Digit|NumType=Card	6	dep	6:dep	Entity=abstract-16)abstract-20)|SpaceAfter=No
8	,	,	PUNCT	,	_	3	punct	3:punct	_
9	are	be	AUX	VBP	Mood=Ind|Number=Plur|Person=3|Tense=Pres|VerbForm=Fin	10	aux:pass	10:aux:pass	Discourse=attribution:12->13
10	used	use	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root	_
11	in	in	SCONJ	IN	_	12	mark	12:mark	Discourse=same_unit:13->10
12	treating	treat	VERB	VBG	VerbForm=Ger	10	advcl	10:advcl:in	_
13	diseases	disease	NOUN	NNS	Number=Plur	12	obj	12:obj	Entity=(abstract-5
14	like	like	ADP	IN	_	16	case	16:case	_
15	immune-related	immune-related	ADJ	JJ	Degree=Pos	16	amod	16:amod	Entity=(abstract-21
16	disorders	disorder	NOUN	NNS	Number=Plur	13	nmod	13:nmod:like	Entity=abstract-21)|SpaceAfter=No
17	,	,	PUNCT	,	_	18	punct	18:punct	_
18	inflammatory	inflammatory	ADJ	JJ	Degree=Pos	16	conj	13:nmod:like|16:conj:and	SpaceAfter=No
19	,	,	PUNCT	,	_	20	punct	20:punct	_
20	respiratory	respiratory	ADJ	JJ	Degree=Pos	16	conj	13:nmod:like|16:conj:and	SpaceAfter=No
21	,	,	PUNCT	,	_	22	punct	22:punct	_
22	AIDS	AIDS	PROPN	NNP	Abbr=Yes|Number=Sing	16	conj	13:nmod:like|16:conj:and	Entity=(abstract-22)|SpaceAfter=No
23	,	,	PUNCT	,	_	24	punct	24:punct	_
24	neurodegenerative	neurodegenerative	ADJ	JJ	Degree=Pos	16	conj	13:nmod:like|16:conj:and	SpaceAfter=No
25	,	,	PUNCT	,	_	28	punct	28:punct	_
26	and	and	CCONJ	CC	_	28	cc	28:cc	_
27	metabolic	metabolic	ADJ	JJ	Degree=Pos	28	amod	28:amod	Entity=(abstract-23
28	disorders	disorder	NOUN	NNS	Number=Plur	16	conj	13:nmod:like|16:conj:and	Entity=abstract-5)abstract-23)|SpaceAfter=No
29	.	.	PUNCT	.	_	10	punct	10:punct	_

# sent_id = AMALGUM_academic_cyclic-6
# s_type = decl
# text = Features like therapeutic potential, good binding affinity, low toxicity, and quickly cleavable by proteolytic enzymes, make cyclic peptides potential future therapeutics.
1	Features	feature	NOUN	NNS	Number=Plur	20	nsubj	20:nsubj|25:nsubj:xsubj	Discourse=joint:14->4|Entity=(abstract-24
2	like	like	ADP	IN	_	4	case	4:case	_
3	therapeutic	therapeutic	ADJ	JJ	Degree=Pos	4	amod	4:amod	Entity=(abstract-25
4	potential	potential	NOUN	NN	Number=Sing	1	nmod	1:nmod:like	Entity=abstract-25)|SpaceAfter=No
5	,	,	PUNCT	,	_	8	punct	8:punct	_
6	good	good	ADJ	JJ	Degree=Pos	8	amod	8:amod	Entity=(abstract-26
7	binding	binding	NOUN	NN	Number=Sing	8	compound	8:compound	Entity=(object-27)
8	affinity	affinity	NOUN	NN	Number=Sing	4	conj	1:nmod:like|4:conj	Entity=abstract-26)|SpaceAfter=No
9	,	,	PUNCT	,	_	11	punct	11:punct	_
10	low	low	ADJ	JJ	Degree=Pos	11	amod	11:amod	Entity=(abstract-28
11	toxicity	toxicity	NOUN	NN	Number=Sing	4	conj	1:nmod:like|4:conj	Entity=abstract-24)abstract-28)|SpaceAfter=No
12	,	,	PUNCT	,	_	15	punct	15:punct	_
13	and	and	CCONJ	CC	_	15	cc	15:cc	_
14	quickly	quickly	ADV	RB	Degree=Pos	15	advmod	15:advmod	_
15	cleavable	cleavable	ADJ	JJ	Degree=Pos	1	conj	1:conj:and|20:nsubj:xsubj|25:nsubj:xsubj	_
16	by	by	ADP	IN	_	18	case	18:case	_
17	proteolytic	proteolytic	ADJ	JJ	Degree=Pos	18	amod	18:amod	Entity=(substance-29
18	enzymes	enzyme	NOUN	NNS	Number=Plur	15	obl	15:obl:by	Entity=substance-29)|SpaceAfter=No
19	,	,	PUNCT	,	_	1	punct	1:punct	_
20	make	make	VERB	VBP	Mood=Ind|Number=Plur|Person=3|Tense=Pres|VerbForm=Fin	0	root	0:root	Discourse=joint:15->4
21	cyclic	cyclic	ADJ	JJ	Degree=Pos	22	amod	22:amod	Entity=(substance-30
22	peptides	peptide	NOUN	NNS	Number=Plur	20	iobj	20:iobj	Entity=substance-30)
23	potential	potential	ADJ	JJ	Degree=Pos	25	amod	25:amod	_
24	future	future	ADJ	JJ	Degree=Pos	25	amod	25:amod	_
25	therapeutics	therapeutics	NOUN	NNS	Number=Plur	20	xcomp	20:xcomp	SpaceAfter=No
26	.	.	PUNCT	.	_	20	punct	20:punct	_

# sent_id = AMALGUM_academic_cyclic-7
# s_type = decl
# text = Most of the cyclic peptides approved by the FDA (shown in Table 2) are used in bacterial and fungal infections, oncology drugs, gastrointestinal disorders, and anemia.
1	Most	most	ADJ	JJS	Degree=Sup	17	nsubj:pass	17:nsubj:pass	Discourse=joint:16->4|Entity=(substance-30
2	of	of	ADP	IN	_	5	case	5:case	_
3	the	the	DET	DT	Definite=Def|PronType=Art	5	det	5:det	_
4	cyclic	cyclic	ADJ	JJ	Degree=Pos	5	amod	5:amod	_
5	peptides	peptide	NOUN	NNS	Number=Plur	1	obl	1:obl:of	_
6	approved	approve	VERB	VBN	Tense=Past|VerbForm=Part	5	acl	5:acl	Discourse=elaboration:17->16
7	by	by	ADP	IN	_	9	case	9:case	_
8	the	the	DET	DT	Definite=Def|PronType=Art	9	det	9:det	Entity=(organization-31
9	FDA	FDA	PROPN	NNP	Number=Sing	6	obl	6:obl:by	Entity=substance-30)organization-31)
10	(	(	PUNCT	-LRB-	_	11	punct	11:punct	Discourse=elaboration:18->16|SpaceAfter=No
11	shown	show	VERB	VBN	Tense=Past|VerbForm=Part	5	dep	5:dep	_
12	in	in	ADP	IN	_	13	case	13:case	_
13	Table	Table	PROPN	NNP	Number=Sing	11	obl	11:obl:in	Entity=(abstract-32
14	2	2	NUM	CD	NumForm=Digit|NumType=Card	13	dep	13:dep	Entity=abstract-32)|SpaceAfter=No
15	)	)	PUNCT	-RRB-	_	11	punct	11:punct	_
16	are	be	AUX	VBP	Mood=Ind|Number=Sing|Person=3|Tense=Pres|VerbForm=Fin	17	aux:pass	17:aux:pass	Discourse=same_unit:19->16
17	used	use	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root	_
18	in	in	ADP	IN	_	22	case	22:case	_
19	bacterial	bacterial	ADJ	JJ	Degree=Pos	22	amod	22:amod	Entity=(abstract-33
20	and	and	CCONJ	CC	_	21	cc	21:cc	_
21	fungal	fungal	ADJ	JJ	Degree=Pos	19	conj	19:conj:and|22:amod	_
22	infections	infection	NOUN	NNS	Number=Plur	17	obl	17:obl:in	Entity=abstract-33)|SpaceAfter=No
23	,	,	PUNCT	,	_	25	punct	25:punct	_
24	oncology	oncology	NOUN	NN	Number=Sing	25	compound	25:compound	Entity=(substance-10(abstract-34)
25	drugs	drug	NOUN	NNS	Number=Plur	22	conj	17:obl:in|22:conj:and	Entity=substance-10)|SpaceAfter=No
26	,	,	PUNCT	,	_	28	punct	28:punct	_
27	gastrointestinal	gastrointestinal	ADJ	JJ	Degree=Pos	28	amod	28:amod	Entity=(abstract-23
28	disorders	disorder	NOUN	NNS	Number=Plur	22	conj	17:obl:in|22:conj:and	Entity=abstract-23)|SpaceAfter=No
29	,	,	PUNCT	,	_	31	punct	31:punct	_
30	and	and	CCONJ	CC	_	31	cc	31:cc	_
31	anemia	anemia	NOUN	NN	Number=Sing	22	conj	17:obl:in|22:conj:and	Entity=(abstract-35)|SpaceAfter=No
32	.	.	PUNCT	.	_	17	punct	17:punct	_

# sent_id = AMALGUM_academic_cyclic-8
# s_type = decl
# text = Recently, cyclic peptides were proven to inhibit HIV-1 protease (aspartyl proteases) and elastase, shedding light onto the use of cyclic peptides as protease inhibitors.
1	Recently	recently	ADV	RB	Degree=Pos	6	advmod	6:advmod	Discourse=elaboration:20->16|SpaceAfter=No
2	,	,	PUNCT	,	_	1	punct	1:punct	_
3	cyclic	cyclic	ADJ	JJ	Degree=Pos	4	amod	4:amod	Entity=(substance-30
4	peptides	peptide	NOUN	NNS	Number=Plur	6	nsubj:pass	6:nsubj:pass|8:nsubj:xsubj	Entity=substance-30)
5	were	be	AUX	VBD	Mood=Ind|Number=Plur|Person=3|Tense=Past|VerbForm=Fin	6	aux:pass	6:aux:pass	_
6	proven	prove	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root	_
7	to	to	PART	TO	_	8	mark	8:mark	_
8	inhibit	inhibit	VERB	VB	VerbForm=Inf	6	xcomp	6:xcomp	_
9	HIV-1	HIV-1	PROPN	NNP	Number=Sing	10	compound	10:compound	Entity=(abstract-15(abstract-36)
10	protease	protease	NOUN	NN	Number=Sing	8	obj	8:obj	Entity=abstract-15)
11	(	(	PUNCT	-LRB-	_	13	punct	13:punct	Discourse=elaboration:21->20|SpaceAfter=No
12	aspartyl	aspartyl	NOUN	NN	Number=Sing	13	compound	13:compound	Entity=(abstract-15(abstract-11)
13	proteases	protease	NOUN	NNS	Number=Plur	10	appos	10:appos	Entity=abstract-15)|SpaceAfter=No
14	)	)	PUNCT	-RRB-	_	13	punct	13:punct	_
15	and	and	CCONJ	CC	_	16	cc	16:cc	Discourse=same_unit:22->20
16	elastase	elastase	NOUN	NN	Number=Sing	10	conj	8:obj|10:conj:and	Entity=(abstract-37)|SpaceAfter=No
17	,	,	PUNCT	,	_	18	punct	18:punct	_
18	shedding	shed	VERB	VBG	VerbForm=Ger	8	advcl	8:advcl	Discourse=elaboration:23->22
19	light	light	NOUN	NN	Number=Sing	18	obj	18:obj	Entity=(abstract-38)
20	onto	onto	ADP	IN	_	22	case	22:case	_
21	the	the	DET	DT	Definite=Def|PronType=Art	22	det	22:det	Entity=(abstract-39
22	use	use	NOUN	NN	Number=Sing	18	obl	18:obl:onto	_
23	of	of	ADP	IN	_	25	case	25:case	_
24	cyclic	cyclic	ADJ	JJ	Degree=Pos	25	amod	25:amod	Entity=(substance-30
25	peptides	peptide	NOUN	NNS	Number=Plur	22	nmod	22:nmod:of	_
26	as	as	ADP	IN	_	28	case	28:case	_
27	protease	protease	NOUN	NN	Number=Sing	28	compound	28:compound	Entity=(abstract-16(abstract-15)
28	inhibitors	inhibitor	NOUN	NNS	Number=Plur	25	nmod	25:nmod:as	Entity=abstract-39)substance-30)abstract-16)|SpaceAfter=No
29	.	.	PUNCT	.	_	6	punct	6:punct	_

# sent_id = AMALGUM_academic_cyclic-9
# s_type = decl
# text = Phage display technology, Incretin-based cyclic peptide, cyclic peptides from mRNA display, and split-pool synthesis are some of the tools used to develop cyclic peptide compounds.
1	Phage	phage	NOUN	NN	Number=Sing	2	compound	2:compound	Discourse=joint:24->4|Entity=(abstract-40(object-41(place-42)
2	display	display	NOUN	NN	Number=Sing	3	compound	3:compound	Entity=object-41)
3	technology	technology	NOUN	NN	Number=Sing	19	nsubj	19:nsubj	Entity=abstract-40)|SpaceAfter=No
4	,	,	PUNCT	,	_	7	punct	7:punct	_
5	Incretin-based	incretin-based	NOUN	NN	Number=Sing	7	compound	7:compound	Entity=(substance-43(abstract-44)
6	cyclic	cyclic	ADJ	JJ	Degree=Pos	7	amod	7:amod	_
7	peptide	peptide	NOUN	NN	Number=Sing	3	conj	3:conj:and|19:nsubj	Entity=substance-43)|SpaceAfter=No
8	,	,	PUNCT	,	_	10	punct	10:punct	_
9	cyclic	cyclic	ADJ	JJ	Degree=Pos	10	amod	10:amod	Entity=(substance-30
10	peptides	peptide	NOUN	NNS	Number=Plur	3	conj	3:conj:and|19:nsubj	_
11	from	from	ADP	IN	_	13	case	13:case	_
12	mRNA	mRNA	NOUN	NN	Number=Sing	13	compound	13:compound	Entity=(object-41(event-45)
13	display	display	NOUN	NN	Number=Sing	10	nmod	10:nmod:from	Entity=substance-30)object-41)|SpaceAfter=No
14	,	,	PUNCT	,	_	17	punct	17:punct	_
15	and	and	CCONJ	CC	_	17	cc	17:cc	_
16	split-pool	split-pool	NOUN	NN	Number=Sing	17	compound	17:compound	Entity=(abstract-46
17	synthesis	synthesis	NOUN	NN	Number=Sing	3	conj	3:conj:and|19:nsubj	Entity=abstract-46)
18	are	be	AUX	VBP	Mood=Ind|Number=Sing|Person=3|Tense=Pres|VerbForm=Fin	19	cop	19:cop	_
19	some	some	PRON	DT	_	0	root	0:root	_
20	of	of	ADP	IN	_	22	case	22:case	_
21	the	the	DET	DT	Definite=Def|PronType=Art	22	det	22:det	Entity=(object-47
22	tools	tool	NOUN	NNS	Number=Plur	19	nmod	19:nmod:of	_
23	used	use	VERB	VBN	Tense=Past|VerbForm=Part	22	acl	22:acl	Discourse=elaboration:25->24
24	to	to	PART	TO	_	25	mark	25:mark	Discourse=purpose:26->25
25	develop	develop	VERB	VB	VerbForm=Inf	23	xcomp	23:xcomp	_
26	cyclic	cyclic	ADJ	JJ	Degree=Pos	27	amod	27:amod	Entity=(substance-48(substance-43
27	peptide	peptide	NOUN	NN	Number=Sing	28	compound	28:compound	Entity=substance-43)
28	compounds	compound	NOUN	NNS	Number=Plur	25	obj	25:obj	Entity=object-47)substance-48)|SpaceAfter=No
29	.	.	PUNCT	.	_	19	punct	19:punct	_

# sent_id = AMALGUM_academic_cyclic-10
# s_type = decl
# text = Recently computer-aided drug design technologies like molecular docking simulations are applied to identify, design rationally (called as de novo developed), and develop cyclic peptide ligand as leads to therapeutic drug targets of interest.
1	Recently	recently	ADV	RB	Degree=Pos	11	advmod	11:advmod	Discourse=joint:27->4
2	computer-aided	computer-aided	ADJ	JJ	Degree=Pos	5	amod	5:amod	Entity=(abstract-49
3	drug	drug	NOUN	NN	Number=Sing	4	compound	4:compound	Entity=(abstract-50(substance-51)
4	design	design	NOUN	NN	Number=Sing	5	compound	5:compound	Entity=abstract-50)
5	technologies	technology	NOUN	NNS	Number=Plur	11	nsubj:pass	11:nsubj:pass|13:nsubj:xsubj|15:nsubj:xsubj|26:nsubj:xsubj	_
6	like	like	ADP	IN	_	9	case	9:case	_
7	molecular	molecular	ADJ	JJ	Degree=Pos	8	amod	8:amod	Entity=(abstract-52(event-53
8	docking	docking	NOUN	NN	Number=Sing	9	compound	9:compound	Entity=event-53)
9	simulations	simulation	NOUN	NNS	Number=Plur	5	nmod	5:nmod:like	Entity=abstract-49)abstract-52)
10	are	be	AUX	VBP	Mood=Ind|Number=Plur|Person=3|Tense=Pres|VerbForm=Fin	11	aux:pass	11:aux:pass	_
11	applied	apply	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root	_
12	to	to	PART	TO	_	13	mark	13:mark	Discourse=purpose:28->27
13	identify	identify	VERB	VB	VerbForm=Inf	11	xcomp	11:xcomp	SpaceAfter=No
14	,	,	PUNCT	,	_	15	punct	15:punct	_
15	design	design	VERB	VB	Mood=Imp|Person=2|VerbForm=Fin	13	conj	11:xcomp|13:conj:and	Discourse=sequence:29->27
16	rationally	rationally	ADV	RB	Degree=Pos	15	advmod	15:advmod	_
17	(	(	PUNCT	-LRB-	_	18	punct	18:punct	Discourse=elaboration:30->29|SpaceAfter=No
18	called	call	VERB	VBN	Tense=Past|VerbForm=Part	13	advcl	13:advcl	_
19	as	as	ADP	IN	_	22	case	22:case	_
20	de	de	NUM	NNP	Number=Sing	21	nummod	21:nummod	Entity=(abstract-54
21	novo	Novo	PROPN	NNP	Number=Sing	22	obl:tmod	22:obl:tmod	Entity=abstract-54)
22	developed	develop	VERB	VBN	Tense=Past|VerbForm=Part	18	advcl	18:advcl	SpaceAfter=No
23	)	)	PUNCT	-RRB-	_	18	punct	18:punct	SpaceAfter=No
24	,	,	PUNCT	,	_	26	punct	26:punct	_
25	and	and	CCONJ	CC	_	26	cc	26:cc	Discourse=sequence:31->27
26	develop	develop	VERB	VB	Mood=Imp|Person=2|VerbForm=Fin	13	conj	11:xcomp|13:conj:and	_
27	cyclic	cyclic	ADJ	JJ	Degree=Pos	29	amod	29:amod	Entity=(substance-55
28	peptide	peptide	NOUN	NN	Number=Sing	29	compound	29:compound	Entity=(substance-43)
29	ligand	ligand	NOUN	NN	Number=Sing	26	obj	26:obj	Entity=substance-55)
30	as	as	ADP	IN	_	31	case	31:case	_
31	leads	lead	NOUN	NNS	Number=Plur	26	obl	26:obl:as	Entity=(abstract-56
32	to	to	ADP	IN	_	35	case	35:case	_
33	therapeutic	therapeutic	ADJ	JJ	Degree=Pos	35	amod	35:amod	Entity=(abstract-57
34	drug	drug	NOUN	NN	Number=Sing	35	compound	35:compound	Entity=(substance-51)
35	targets	target	NOUN	NNS	Number=Plur	31	nmod	31:nmod:to	_
36	of	of	ADP	IN	_	37	case	37:case	_
37	interest	interest	NOUN	NN	Number=Sing	35	nmod	35:nmod:of	Entity=abstract-56)abstract-57)|SpaceAfter=No
38	.	.	PUNCT	.	_	11	punct	11:punct	_

# sent_id = AMALGUM_academic_cyclic-11
# s_type = decl
# text = Till today, cyclic peptides as therapeutics in regulating glucose metabolism by inhibiting proteases have not been reported for the treatment of diabetes mellitus.
1	Till	till	ADP	IN	_	2	case	2:case	Discourse=sequence:32->27
2	today	today	NOUN	NN	Number=Sing	18	obl	18:obl:till	Entity=(time-58)|SpaceAfter=No
3	,	,	PUNCT	,	_	2	punct	2:punct	_
4	cyclic	cyclic	ADJ	JJ	Degree=Pos	5	amod	5:amod	Entity=(substance-30
5	peptides	peptide	NOUN	NNS	Number=Plur	18	nsubj:pass	18:nsubj:pass	_
6	as	as	ADP	IN	_	7	case	7:case	_
7	therapeutics	therapeutics	NOUN	NNS	Number=Plur	5	nmod	5:nmod:as	Entity=(abstract-19
8	in	in	SCONJ	IN	_	9	mark	9:mark	Discourse=elaboration:33->32
9	regulating	regulate	VERB	VBG	VerbForm=Ger	7	acl	7:acl:in	_
10	glucose	glucose	NOUN	NN	Number=Sing	11	compound	11:compound	Entity=(abstract-59(substance-60)
11	metabolism	metabolism	NOUN	NN	Number=Sing	9	obj	9:obj	Entity=substance-30)abstract-19)abstract-59)
12	by	by	SCONJ	IN	_	13	mark	13:mark	Discourse=same_unit:34->33
13	inhibiting	inhibit	VERB	VBG	VerbForm=Ger	9	advcl	9:advcl:by	_
14	proteases	protease	NOUN	NNS	Number=Plur	13	obj	13:obj	Entity=(abstract-15)
15	have	have	AUX	VBP	Mood=Ind|Number=Plur|Person=3|Tense=Pres|VerbForm=Fin	18	aux	18:aux	_
16	not	not	ADV	RB	Polarity=Neg	18	advmod	18:advmod	_
17	been	be	AUX	VBN	Tense=Past|VerbForm=Part	18	aux:pass	18:aux:pass	_
18	reported	report	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root	_
19	for	for	ADP	IN	_	21	case	21:case	_
20	the	the	DET	DT	Definite=Def|PronType=Art	21	det	21:det	Entity=(abstract-61
21	treatment	treatment	NOUN	NN	Number=Sing	18	obl	18:obl:for	_
22	of	of	ADP	IN	_	23	case	23:case	_
23	diabetes	diabet	NOUN	NNS	Number=Plur	21	nmod	21:nmod:of	Entity=(abstract-8
24	mellitus	mellitus	NOUN	NN	Number=Sing	23	flat	23:flat	Entity=abstract-61)abstract-8)|SpaceAfter=No
25	.	.	PUNCT	.	_	18	punct	18:punct	_

# sent_id = AMALGUM_academic_cyclic-12
# s_type = decl
# text = In Mexico, approximately 11.5 million people live with diabetes mellitus (DM), which is the main leading cause of acquired blindness, non-traumatic lower-limb amputations, and chronic kidney failure diseases.
1	In	in	ADP	IN	_	2	case	2:case	Discourse=sequence:35->27
2	Mexico	Mexico	PROPN	NNP	Number=Sing	8	obl	8:obl:in	Entity=(place-62)|SpaceAfter=No
3	,	,	PUNCT	,	_	2	punct	2:punct	_
4	approximately	approximately	ADV	RB	Degree=Pos	6	advmod	6:advmod	Entity=(person-63
5	11.5	11.5	NUM	CD	NumForm=Digit|NumType=Card	6	compound	6:compound	_
6	million	1000000	NUM	CD	NumForm=Digit|NumType=Card	7	nummod	7:nummod	_
7	people	person	NOUN	NNS	Number=Plur	8	nsubj	8:nsubj	Entity=person-63)
8	live	live	VERB	VBP	Mood=Ind|Number=Plur|Person=3|Tense=Pres|VerbForm=Fin	0	root	0:root	_
9	with	with	ADP	IN	_	10	case	10:case	_
10	diabetes	diabet	NOUN	NNS	Number=Plur	8	obl	8:obl:with|21:nsubj	Entity=(abstract-8
11	mellitus	mellitus	NOUN	NN	Number=Sing	10	flat	10:flat	Entity=abstract-8)
12	(	(	PUNCT	-LRB-	_	13	punct	13:punct	Discourse=elaboration:36->35|SpaceAfter=No
13	DM	DM	PROPN	NNP	Number=Sing	10	appos	10:appos	Entity=(person-64)|SpaceAfter=No
14	)	)	PUNCT	-RRB-	_	13	punct	13:punct	SpaceAfter=No
15	,	,	PUNCT	,	_	21	punct	21:punct	_
16	which	which	PRON	WDT	PronType=Rel	21	nsubj	10:ref	Discourse=elaboration:37->35|Entity=(abstract-65
17	is	be	AUX	VBZ	Mood=Ind|Number=Sing|Person=3|Tense=Pres|VerbForm=Fin	21	cop	21:cop	_
18	the	the	DET	DT	Definite=Def|PronType=Art	21	det	21:det	_
19	main	main	ADJ	JJ	Degree=Pos	21	amod	21:amod	_
20	leading	lead	VERB	VBG	VerbForm=Ger	21	amod	21:amod	_
21	cause	cause	NOUN	NN	Number=Sing	10	acl:relcl	10:acl:relcl	_
22	of	of	ADP	IN	_	24	case	24:case	_
23	acquired	acquire	VERB	VBN	Tense=Past|VerbForm=Part	24	amod	24:amod	Entity=(abstract-66
24	blindness	blindness	NOUN	NN	Number=Sing	21	nmod	21:nmod:of	Entity=abstract-66)|SpaceAfter=No
25	,	,	PUNCT	,	_	28	punct	28:punct	_
26	non-traumatic	non-traumatic	ADJ	JJ	Degree=Pos|Polarity=Neg	28	amod	28:amod	Entity=(event-67
27	lower-limb	lower-limb	NOUN	NN	Number=Sing	28	compound	28:compound	Entity=(event-68)
28	amputations	amputation	NOUN	NNS	Number=Plur	24	conj	21:nmod:of|24:conj:and	Entity=event-67)|SpaceAfter=No
29	,	,	PUNCT	,	_	34	punct	34:punct	_
30	and	and	CCONJ	CC	_	34	cc	34:cc	_
31	chronic	chronic	ADJ	JJ	Degree=Pos	34	amod	34:amod	Entity=(abstract-5
32	kidney	kidney	NOUN	NN	Number=Sing	33	compound	33:compound	Entity=(event-69(object-70)
33	failure	failure	NOUN	NN	Number=Sing	34	compound	34:compound	Entity=event-69)
34	diseases	disease	NOUN	NNS	Number=Plur	24	conj	21:nmod:of|24:conj:and	Entity=abstract-65)abstract-5)|SpaceAfter=No
35	.	.	PUNCT	.	_	8	punct	8:punct	_

# sent_id = AMALGUM_academic_cyclic-13
# s_type = decl
# text = Human dipeptidyl peptidase-4 (DPP4) is a serine protease, well known FDA-approved therapeutic drug target for regulating blood glucose metabolism and treating diabetes mellitus.
1	Human	Human	ADJ	JJ	Degree=Pos	3	amod	3:amod	Discourse=joint:38->4|Entity=(abstract-71
2	dipeptidyl	dipeptidyl	NOUN	NN	Number=Sing	3	compound	3:compound	Entity=(abstract-72)
3	peptidase-4	peptidase-4	NOUN	NN	Number=Sing	10	nsubj	10:nsubj	Entity=abstract-71)
4	(	(	PUNCT	-LRB-	_	5	punct	5:punct	Discourse=restatement:39->38|SpaceAfter=No
5	DPP4	DPP4	PROPN	NNP	Number=Sing	3	appos	3:appos	Entity=(abstract-71)|SpaceAfter=No
6	)	)	PUNCT	-RRB-	_	5	punct	5:punct	_
7	is	be	AUX	VBZ	Mood=Ind|Number=Sing|Person=3|Tense=Pres|VerbForm=Fin	10	cop	10:cop	Discourse=same_unit:40->38
8	a	a	DET	DT	Definite=Ind|PronType=Art	10	det	10:det	Entity=(abstract-71
9	serine	serine	NOUN	NN	Number=Sing	10	compound	10:compound	Entity=(animal-12)
10	protease	protease	NOUN	NN	Number=Sing	0	root	0:root	Entity=abstract-71)|SpaceAfter=No
11	,	,	PUNCT	,	_	17	punct	17:punct	_
12	well	well	ADV	RB	Degree=Pos	13	advmod	13:advmod	Entity=(abstract-71
13	known	know	VERB	VBN	Tense=Past|VerbForm=Part	17	amod	17:amod	_
14	FDA-approved	FDA-approved	PROPN	NNP	Number=Sing	17	compound	17:compound	Entity=(organization-73)
15	therapeutic	therapeutic	ADJ	JJ	Degree=Pos	16	amod	16:amod	Entity=(substance-51
16	drug	drug	NOUN	NN	Number=Sing	17	compound	17:compound	Entity=substance-51)
17	target	target	NOUN	NN	Number=Sing	10	appos	10:appos	Entity=abstract-71)
18	for	for	SCONJ	IN	_	19	mark	19:mark	Discourse=purpose:41->38
19	regulating	regulate	VERB	VBG	VerbForm=Ger	10	acl	10:acl:for	_
20	blood	blood	NOUN	NN	Number=Sing	21	compound	21:compound	Entity=(abstract-59(substance-60(substance-74)
21	glucose	glucose	NOUN	NN	Number=Sing	22	compound	22:compound	Entity=substance-60)
22	metabolism	metabolism	NOUN	NN	Number=Sing	19	obj	19:obj	Entity=abstract-59)
23	and	and	CCONJ	CC	_	24	cc	24:cc	Discourse=joint:42->41
24	treating	treat	VERB	VBG	VerbForm=Ger	19	conj	10:acl:for|19:conj:and	_
25	diabetes	diabet	NOUN	NNS	Number=Plur	24	obj	24:obj	Entity=(abstract-8)
26	mellitus	mellitus	NOUN	NN	Number=Sing	24	obj	24:obj	Entity=(abstract-75)|SpaceAfter=No
27	.	.	PUNCT	.	_	10	punct	10:punct	_

# sent_id = AMALGUM_academic_cyclic-14
# s_type = decl
# text = Sitagliptin, Vildagliptin, Anagliptin, Saxagliptin, and Alogliptin are the main clinically used chemicals for human dipeptidyl peptidase-4 (DPP4) inhibition despite their side effects as pancreatitis, nausea, and anemia.
1	Sitagliptin	Sitagliptin	PROPN	NNP	Number=Sing	16	nsubj	16:nsubj	Discourse=joint:43->4|Entity=(abstract-76)|SpaceAfter=No
2	,	,	PUNCT	,	_	3	punct	3:punct	_
3	Vildagliptin	Vildagliptin	PROPN	NNP	Number=Sing	1	conj	1:conj:and|16:nsubj	Entity=(substance-77)|SpaceAfter=No
4	,	,	PUNCT	,	_	5	punct	5:punct	_
5	Anagliptin	Anagliptin	PROPN	NNP	Number=Sing	1	conj	1:conj:and|16:nsubj	Entity=(plant-78)|SpaceAfter=No
6	,	,	PUNCT	,	_	7	punct	7:punct	_
7	Saxagliptin	Saxagliptin	PROPN	NNP	Number=Sing	1	conj	1:conj:and|16:nsubj	Entity=(plant-79)|SpaceAfter=No
8	,	,	PUNCT	,	_	10	punct	10:punct	_
9	and	and	CCONJ	CC	_	10	cc	10:cc	_
10	Alogliptin	Alogliptin	PROPN	NNP	Number=Sing	1	conj	1:conj:and|16:nsubj	Entity=(substance-80)
11	are	be	AUX	VBP	Mood=Ind|Number=Sing|Person=3|Tense=Pres|VerbForm=Fin	16	cop	16:cop	_
12	the	the	DET	DT	Definite=Def|PronType=Art	16	det	16:det	Entity=(substance-80
13	main	main	ADJ	JJ	Degree=Pos	16	amod	16:amod	_
14	clinically	clinically	ADV	RB	Degree=Pos	15	advmod	15:advmod	_
15	used	use	VERB	VBN	Tense=Past|VerbForm=Part	16	amod	16:amod	_
16	chemicals	chemical	NOUN	NNS	Number=Plur	0	root	0:root	_
17	for	for	ADP	IN	_	24	case	24:case	_
18	human	human	ADJ	JJ	Degree=Pos	24	amod	24:amod	Entity=(abstract-81
19	dipeptidyl	dipeptidyl	NOUN	NN	Number=Sing	20	compound	20:compound	Entity=(abstract-71(abstract-72)
20	peptidase-4	peptidase-4	NOUN	NN	Number=Sing	24	compound	24:compound	Entity=abstract-71)
21	(	(	PUNCT	-LRB-	_	22	punct	22:punct	Discourse=restatement:44->43|SpaceAfter=No
22	DPP4	DPP4	PROPN	NNP	Number=Sing	20	appos	20:appos	Entity=(abstract-71)|SpaceAfter=No
23	)	)	PUNCT	-RRB-	_	22	punct	22:punct	_
24	inhibition	inhibition	NOUN	NN	Number=Sing	16	nmod	16:nmod:for	Discourse=same_unit:45->43|Entity=abstract-81)
25	despite	despite	ADP	IN	_	28	case	28:case	Discourse=concession:46->45
26	their	their	PRON	PRP$	Number=Plur|Person=3|Poss=Yes|PronType=Prs	28	nmod:poss	28:nmod:poss	Entity=(abstract-82(substance-80)
27	side	side	NOUN	NN	Number=Sing	28	compound	28:compound	Entity=(abstract-83)
28	effects	effect	NOUN	NNS	Number=Plur	16	nmod	16:nmod:despite	_
29	as	as	ADP	IN	_	30	case	30:case	_
30	pancreatitis	pancreatitis	NOUN	NN	Number=Sing	28	nmod	28:nmod:as	Entity=(abstract-84)|SpaceAfter=No
31	,	,	PUNCT	,	_	32	punct	32:punct	_
32	nausea	nausea	NOUN	NN	Number=Sing	30	conj	28:nmod:as|30:conj:and	Entity=(event-85)|SpaceAfter=No
33	,	,	PUNCT	,	_	35	punct	35:punct	_
34	and	and	CCONJ	CC	_	35	cc	35:cc	_
35	anemia	anemia	NOUN	NN	Number=Sing	30	conj	28:nmod:as|30:conj:and	Entity=substance-80)abstract-82)(abstract-35)|SpaceAfter=No
36	.	.	PUNCT	.	_	16	punct	16:punct	_

# sent_id = AMALGUM_academic_cyclic-15
# s_type = decl
# text = It is well known that incretin hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are responsible for insulin release and glucose regulation.
1	It	it	PRON	PRP	Case=Acc|Gender=Neut|Number=Sing|Person=3|PronType=Prs	4	expl	4:expl	Discourse=attribution:47->48|Entity=(abstract-35)
2	is	be	AUX	VBZ	Mood=Ind|Number=Sing|Person=3|Tense=Pres|VerbForm=Fin	4	aux:pass	4:aux:pass	_
3	well	well	ADV	RB	Degree=Pos	4	advmod	4:advmod	_
4	known	know	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root	_
5	that	that	SCONJ	IN	_	22	mark	22:mark	Discourse=joint:48->4
6	incretin	incretin	ADJ	JJ	Degree=Pos	7	amod	7:amod	Entity=(substance-86
7	hormones	hormone	NOUN	NNS	Number=Plur	22	nsubj	22:nsubj	Entity=substance-86)
8	glucagon-like	glucagon-like	ADJ	JJ	Degree=Pos	9	amod	9:amod	Entity=(substance-43
9	peptide	peptide	NOUN	NN	Number=Sing	22	nsubj	22:nsubj	_
10	1	1	NUM	CD	NumForm=Digit|NumType=Card	9	dep	9:dep	Entity=substance-43)
11	(	(	PUNCT	-LRB-	_	12	punct	12:punct	Discourse=restatement:49->48|SpaceAfter=No
12	GLP-1	GLP-1	PROPN	NNP	Number=Sing	9	appos	9:appos	Entity=(abstract-87)|SpaceAfter=No
13	)	)	PUNCT	-RRB-	_	12	punct	12:punct	_
14	and	and	CCONJ	CC	_	17	cc	17:cc	Discourse=same_unit:50->48
15	glucose-dependent	glucose-dependent	ADJ	JJ	Degree=Pos	17	amod	17:amod	Entity=(place-88
16	insulinotropic	insulinotropic	ADJ	JJ	Degree=Pos	17	amod	17:amod	_
17	polypeptide	polypeptide	NOUN	NN	Number=Sing	9	conj	9:conj:and|22:nsubj	Entity=place-88)
18	(	(	PUNCT	-LRB-	_	19	punct	19:punct	Discourse=restatement:51->50|SpaceAfter=No
19	GIP	GIP	PROPN	NNP	Number=Sing	17	appos	17:appos	Entity=(abstract-89)|SpaceAfter=No
20	)	)	PUNCT	-RRB-	_	19	punct	19:punct	_
21	are	be	AUX	VBP	Mood=Ind|Number=Plur|Person=3|Tense=Pres|VerbForm=Fin	22	cop	22:cop	Discourse=same_unit:52->48
22	responsible	responsible	ADJ	JJ	Degree=Pos	4	csubj:pass	4:csubj:pass	_
23	for	for	ADP	IN	_	25	case	25:case	_
24	insulin	insulin	NOUN	NN	Number=Sing	25	compound	25:compound	Entity=(event-90(substance-91)
25	release	release	NOUN	NN	Number=Sing	22	obl	22:obl:for	Entity=event-90)
26	and	and	CCONJ	CC	_	28	cc	28:cc	_
27	glucose	glucose	NOUN	NN	Number=Sing	28	compound	28:compound	Entity=(abstract-92(substance-60)
28	regulation	regulation	NOUN	NN	Number=Sing	25	conj	22:obl:for|25:conj:and	Entity=abstract-92)|SpaceAfter=No
29	.	.	PUNCT	.	_	4	punct	4:punct	_

# sent_id = AMALGUM_academic_cyclic-16
# s_type = decl
# text = These hormones are inactivated by a serine protease human dipeptidyl peptidase-4 (DPP4).
1	These	this	DET	DT	Number=Plur|PronType=Dem	2	det	2:det	Discourse=joint:53->4|Entity=(substance-86
2	hormones	hormone	NOUN	NNS	Number=Plur	4	nsubj:pass	4:nsubj:pass	Entity=substance-86)
3	are	be	AUX	VBP	Mood=Ind|Number=Plur|Person=3|Tense=Pres|VerbForm=Fin	4	aux:pass	4:aux:pass	_
4	inactivated	inactivate	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root	_
5	by	by	ADP	IN	_	8	case	8:case	_
6	a	a	DET	DT	Definite=Ind|PronType=Art	8	det	8:det	Entity=(abstract-71
7	serine	serine	NOUN	NN	Number=Sing	8	compound	8:compound	Entity=(animal-12)
8	protease	protease	NOUN	NN	Number=Sing	4	obl	4:obl:by	Entity=abstract-71)
9	human	human	ADJ	JJ	Degree=Pos	11	amod	11:amod	Entity=(abstract-71
10	dipeptidyl	dipeptidyl	NOUN	NN	Number=Sing	11	compound	11:compound	Entity=(abstract-72)
11	peptidase-4	peptidase-4	NOUN	NN	Number=Sing	8	appos	8:appos	Entity=abstract-71)
12	(	(	PUNCT	-LRB-	_	13	punct	13:punct	Discourse=restatement:54->53|SpaceAfter=No
13	DPP4	DPP4	X	FW	_	11	appos	11:appos	SpaceAfter=No
14	)	)	PUNCT	-RRB-	_	13	punct	13:punct	SpaceAfter=No
15	.	.	PUNCT	.	_	4	punct	4:punct	_

# sent_id = AMALGUM_academic_cyclic-17
# s_type = decl
# text = Since natural cyclic peptides are proven to inhibit various proteases, and to consider the beneficial aspects of cyclic peptides in comparison to small chemicals, like less toxicity, no accumulation in organs, and rapid degradation of peptides, we hypothesized that cyclic peptides from natural sources could be an alternative source of therapeutics to inhibit serine protease DPP4 for treatment of diabetes mellitus.
1	Since	since	SCONJ	IN	_	6	mark	6:mark	Discourse=joint:55->4
2	natural	natural	ADJ	JJ	Degree=Pos	4	amod	4:amod	Entity=(substance-30
3	cyclic	cyclic	ADJ	JJ	Degree=Pos	4	amod	4:amod	_
4	peptides	peptide	NOUN	NNS	Number=Plur	6	nsubj:pass	6:nsubj:pass|8:nsubj:xsubj	Entity=substance-30)
5	are	be	AUX	VBP	Mood=Ind|Number=Plur|Person=3|Tense=Pres|VerbForm=Fin	6	aux:pass	6:aux:pass|14:aux:pass	_
6	proven	prove	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	43	advcl	43:advcl:since	_
7	to	to	PART	TO	_	8	mark	8:mark	_
8	inhibit	inhibit	VERB	VB	VerbForm=Inf	6	xcomp	6:xcomp	_
9	various	various	ADJ	JJ	Degree=Pos	10	amod	10:amod	Entity=(abstract-15
10	proteases	protease	NOUN	NNS	Number=Plur	8	obj	8:obj	Entity=abstract-15)|SpaceAfter=No
11	,	,	PUNCT	,	_	14	punct	14:punct	_
12	and	and	CCONJ	CC	_	14	cc	14:cc	Discourse=preparation:56->58
13	to	to	PART	TO	_	14	mark	14:mark	_
14	consider	consider	VERB	VB	Mood=Imp|Person=2|VerbForm=Fin	6	conj	6:conj:and|43:advcl:since	_
15	the	the	DET	DT	Definite=Def|PronType=Art	17	det	17:det	Entity=(abstract-93
16	beneficial	beneficial	ADJ	JJ	Degree=Pos	17	amod	17:amod	_
17	aspects	aspect	NOUN	NNS	Number=Plur	14	obj	14:obj	_
18	of	of	ADP	IN	_	20	case	20:case	_
19	cyclic	cyclic	ADJ	JJ	Degree=Pos	20	amod	20:amod	Entity=(substance-30
20	peptides	peptide	NOUN	NNS	Number=Plur	17	nmod	17:nmod:of	Entity=substance-30)
21	in	in	ADP	IN	_	22	case	22:case	_
22	comparison	comparison	NOUN	NN	Number=Sing	14	obl	14:obl:in	_
23	to	to	ADP	IN	_	25	case	25:case	_
24	small	small	ADJ	JJ	Degree=Pos	25	amod	25:amod	Entity=(substance-80
25	chemicals	chemical	NOUN	NNS	Number=Plur	22	nmod	22:nmod:to	Entity=substance-80)|SpaceAfter=No
26	,	,	PUNCT	,	_	29	punct	29:punct	_
27	like	like	ADP	IN	_	29	case	29:case	_
28	less	less	ADJ	JJR	Degree=Cmp	29	amod	29:amod	Entity=(abstract-28
29	toxicity	toxicity	NOUN	NN	Number=Sing	17	nmod	17:nmod:like	Entity=abstract-28)|SpaceAfter=No
30	,	,	PUNCT	,	_	32	punct	32:punct	_
31	no	no	DET	DT	Polarity=Neg	32	det	32:det	Entity=(abstract-94
32	accumulation	accumulation	NOUN	NN	Number=Sing	29	conj	17:nmod:like|29:conj:and	_
33	in	in	ADP	IN	_	34	case	34:case	_
34	organs	organ	NOUN	NNS	Number=Plur	32	nmod	32:nmod:in	Entity=abstract-94)(object-95)|SpaceAfter=No
35	,	,	PUNCT	,	_	38	punct	38:punct	_
36	and	and	CCONJ	CC	_	38	cc	38:cc	_
37	rapid	rapid	ADJ	JJ	Degree=Pos	38	amod	38:amod	Entity=(event-96
38	degradation	degradation	NOUN	NN	Number=Sing	29	conj	17:nmod:like|29:conj:and	_
39	of	of	ADP	IN	_	40	case	40:case	_
40	peptides	peptide	NOUN	NNS	Number=Plur	38	nmod	38:nmod:of	Entity=abstract-93)event-96)(substance-30)|SpaceAfter=No
41	,	,	PUNCT	,	_	6	punct	6:punct	_
42	we	we	PRON	PRP	Case=Nom|Number=Plur|Person=1|PronType=Prs	43	nsubj	43:nsubj	Discourse=attribution:57->58|Entity=(person-97)
43	hypothesized	hypothesize	VERB	VBD	Mood=Ind|Number=Plur|Person=1|Tense=Past|VerbForm=Fin	0	root	0:root	_
44	that	that	SCONJ	IN	_	54	mark	54:mark	Discourse=joint:58->4
45	cyclic	cyclic	ADJ	JJ	Degree=Pos	46	amod	46:amod	Entity=(substance-30
46	peptides	peptide	NOUN	NNS	Number=Plur	54	nsubj	54:nsubj	_
47	from	from	ADP	IN	_	49	case	49:case	_
48	natural	natural	ADJ	JJ	Degree=Pos	49	amod	49:amod	Entity=(abstract-98
49	sources	source	NOUN	NNS	Number=Plur	46	nmod	46:nmod:from	Entity=substance-30)abstract-98)
50	could	could	AUX	MD	VerbForm=Fin	54	aux	54:aux	_
51	be	be	AUX	VB	VerbForm=Inf	54	cop	54:cop	_
52	an	a	DET	DT	Definite=Ind|PronType=Art	54	det	54:det	Entity=(substance-30
53	alternative	alternative	ADJ	JJ	Degree=Pos	54	amod	54:amod	_
54	source	source	NOUN	NN	Number=Sing	43	ccomp	43:ccomp	_
55	of	of	ADP	IN	_	56	case	56:case	_
56	therapeutics	therapeutics	NOUN	NNS	Number=Plur	54	nmod	54:nmod:of	Entity=(abstract-19)
57	to	to	PART	TO	_	58	mark	58:mark	Discourse=purpose:59->58
58	inhibit	inhibit	VERB	VB	VerbForm=Inf	54	acl	54:acl:to	_
59	serine	serine	NOUN	NN	Number=Sing	60	compound	60:compound	Entity=(abstract-71(animal-12)
60	protease	protease	NOUN	NN	Number=Sing	58	obj	58:obj	Entity=abstract-71)
61	DPP4	DPP4	PROPN	NNP	Number=Sing	58	obj	58:obj	Entity=(abstract-71)
62	for	for	ADP	IN	_	63	case	63:case	_
63	treatment	treatment	NOUN	NN	Number=Sing	58	obl	58:obl:for	Entity=(event-99
64	of	of	ADP	IN	_	66	case	66:case	_
65	diabetes	diabet	NOUN	NNS	Number=Plur	66	compound	66:compound	Entity=(abstract-75(abstract-8)
66	mellitus	mellitus	NOUN	NN	Number=Sing	63	nmod	63:nmod:of	Entity=substance-30)event-99)abstract-75)|SpaceAfter=No
67	.	.	PUNCT	.	_	43	punct	43:punct	_

# sent_id = AMALGUM_academic_cyclic-18
# s_type = decl
# text = Among various naturally occurring cyclic peptides, oxytocin (natural cyclic peptide) was chosen in this study to prove our hypothesis that, cyclic peptides possess serine protease inhibition activity, and specifically inhibit DPP4.
1	Among	among	ADP	IN	_	6	case	6:case	Discourse=joint:60->58
2	various	various	DET	JJ	Degree=Pos	6	det	6:det	Entity=(substance-30
3	naturally	naturally	ADV	RB	Degree=Pos	4	advmod	4:advmod	_
4	occurring	occur	VERB	VBG	VerbForm=Ger	6	amod	6:amod	_
5	cyclic	cyclic	ADJ	JJ	Degree=Pos	6	amod	6:amod	_
6	peptides	peptide	NOUN	NNS	Number=Plur	15	obl	15:obl:among	Entity=substance-30)|SpaceAfter=No
7	,	,	PUNCT	,	_	6	punct	6:punct	_
8	oxytocin	oxytocin	NOUN	NN	Number=Sing	15	nsubj:pass	15:nsubj:pass|20:nsubj:xsubj	Discourse=joint:61->58|Entity=(substance-100)
9	(	(	PUNCT	-LRB-	_	12	punct	12:punct	Discourse=elaboration:62->61|SpaceAfter=No
10	natural	natural	ADJ	JJ	Degree=Pos	12	amod	12:amod	Entity=(substance-43
11	cyclic	cyclic	NOUN	NN	Number=Sing	12	compound	12:compound	Entity=(person-101)
12	peptide	peptide	NOUN	NN	Number=Sing	8	appos	8:appos	Entity=substance-43)|SpaceAfter=No
13	)	)	PUNCT	-RRB-	_	12	punct	12:punct	_
14	was	be	AUX	VBD	Mood=Ind|Number=Sing|Person=3|Tense=Past|VerbForm=Fin	15	aux:pass	15:aux:pass	Discourse=same_unit:63->61
15	chosen	choose	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root	_
16	in	in	ADP	IN	_	18	case	18:case	_
17	this	this	DET	DT	Number=Sing|PronType=Dem	18	det	18:det	Entity=(abstract-102
18	study	study	NOUN	NN	Number=Sing	15	obl	15:obl:in	Entity=abstract-102)
19	to	to	PART	TO	_	20	mark	20:mark	Discourse=purpose:64->61
20	prove	prove	VERB	VB	VerbForm=Inf	15	xcomp	15:xcomp	_
21	our	our	PRON	PRP$	Number=Plur|Person=1|Poss=Yes|PronType=Prs	22	nmod:poss	22:nmod:poss	Entity=(abstract-103(person-97)
22	hypothesis	hypothesis	NOUN	NN	Number=Sing	20	obj	20:obj	_
23	that	that	SCONJ	IN	_	27	mark	27:mark	Discourse=joint:65->64|SpaceAfter=No
24	,	,	PUNCT	,	_	23	punct	23:punct	_
25	cyclic	cyclic	ADJ	JJ	Degree=Pos	26	amod	26:amod	Entity=(substance-30
26	peptides	peptide	NOUN	NNS	Number=Plur	27	nsubj	27:nsubj|35:nsubj	Entity=substance-30)
27	possess	possess	VERB	VBP	Mood=Ind|Number=Plur|Person=3|Tense=Pres|VerbForm=Fin	22	acl	22:acl:that	_
28	serine	serine	NOUN	NN	Number=Sing	31	compound	31:compound	Entity=(abstract-104(animal-12)
29	protease	protease	NOUN	NN	Number=Sing	31	compound	31:compound	Entity=(abstract-71)
30	inhibition	inhibition	NOUN	NN	Number=Sing	31	compound	31:compound	Entity=(abstract-81)
31	activity	activity	NOUN	NN	Number=Sing	27	obj	27:obj	Entity=abstract-104)|SpaceAfter=No
32	,	,	PUNCT	,	_	35	punct	35:punct	_
33	and	and	CCONJ	CC	_	35	cc	35:cc	Discourse=joint:66->65
34	specifically	specifically	ADV	RB	Degree=Pos	35	advmod	35:advmod	_
35	inhibit	inhibit	VERB	VBP	Mood=Ind|Number=Plur|Person=3|Tense=Pres|VerbForm=Fin	27	conj	22:acl:that|27:conj:and	_
36	DPP4	DPP4	PROPN	NNP	Number=Sing	35	obj	35:obj	Entity=abstract-103)(abstract-71)|SpaceAfter=No
37	.	.	PUNCT	.	_	15	punct	15:punct	_

# sent_id = AMALGUM_academic_cyclic-19
# s_type = decl
# text = To demonstrate our hypothesis, activity atlas and field-based models of DPP4 inhibitors from natural origin were utilized to elucidate molecular insights of oxytocin peptide into DPP4 inhibition.
1	To	to	PART	TO	_	2	mark	2:mark	Discourse=purpose:67->66
2	demonstrate	demonstrate	VERB	VB	VerbForm=Inf	18	advcl	18:advcl:to	_
3	our	our	PRON	PRP$	Number=Plur|Person=1|Poss=Yes|PronType=Prs	4	nmod:poss	4:nmod:poss	Entity=(abstract-103(person-97)
4	hypothesis	hypothesis	NOUN	NN	Number=Sing	2	obj	2:obj	Entity=abstract-103)|SpaceAfter=No
5	,	,	PUNCT	,	_	2	punct	2:punct	_
6	activity	activity	NOUN	NN	Number=Sing	7	compound	7:compound	Discourse=joint:68->67|Entity=(abstract-105(abstract-104)
7	atlas	atla	NOUN	NN	Number=Sing	18	nsubj:pass	18:nsubj:pass|20:nsubj:xsubj	Entity=abstract-105)
8	and	and	CCONJ	CC	_	10	cc	10:cc	_
9	field-based	field-based	ADJ	JJ	Degree=Pos	10	amod	10:amod	Entity=(abstract-106
10	models	model	NOUN	NNS	Number=Plur	7	conj	7:conj:and|18:nsubj:xsubj|20:nsubj:xsubj	_
11	of	of	ADP	IN	_	13	case	13:case	_
12	DPP4	DPP4	PROPN	NNP	Number=Sing	13	compound	13:compound	Entity=(abstract-16(abstract-71)
13	inhibitors	inhibitor	NOUN	NNS	Number=Plur	10	nmod	10:nmod:of	_
14	from	from	ADP	IN	_	16	case	16:case	_
15	natural	natural	ADJ	JJ	Degree=Pos	16	amod	16:amod	Entity=(abstract-107
16	origin	origin	NOUN	NN	Number=Sing	13	nmod	13:nmod:from	Entity=abstract-106)abstract-16)abstract-107)
17	were	be	AUX	VBD	Mood=Ind|Number=Plur|Person=3|Tense=Past|VerbForm=Fin	18	aux:pass	18:aux:pass	_
18	utilized	utilize	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root	_
19	to	to	PART	TO	_	20	mark	20:mark	Discourse=purpose:69->68
20	elucidate	elucidate	VERB	VB	VerbForm=Inf	18	xcomp	18:xcomp	_
21	molecular	molecular	ADJ	JJ	Degree=Pos	22	amod	22:amod	Entity=(abstract-108
22	insights	insight	NOUN	NNS	Number=Plur	20	obj	20:obj	_
23	of	of	ADP	IN	_	25	case	25:case	_
24	oxytocin	oxytocin	NOUN	NN	Number=Sing	25	compound	25:compound	Entity=(substance-43(substance-100)
25	peptide	peptide	NOUN	NN	Number=Sing	22	nmod	22:nmod:of	Entity=abstract-108)substance-43)
26	into	into	ADP	IN	_	28	case	28:case	_
27	DPP4	DPP4	PROPN	NNP	Number=Sing	28	compound	28:compound	Entity=(abstract-81(abstract-71)
28	inhibition	inhibition	NOUN	NN	Number=Sing	20	obl	20:obl:into	Entity=abstract-81)|SpaceAfter=No
29	.	.	PUNCT	.	_	18	punct	18:punct	_

# sent_id = AMALGUM_academic_cyclic-20
# s_type = decl
# text = In addition, molecular docking simulations were used to understand the binding poses and interacting residues responsible for inhibitory activity.
1	In	in	ADP	IN	_	2	case	2:case	Discourse=joint:70->68
2	addition	addition	NOUN	NN	Number=Sing	8	obl	8:obl:in	SpaceAfter=No
3	,	,	PUNCT	,	_	2	punct	2:punct	_
4	molecular	molecular	ADJ	JJ	Degree=Pos	5	amod	5:amod	Entity=(abstract-52(event-53
5	docking	docking	NOUN	NN	Number=Sing	6	compound	6:compound	Entity=event-53)
6	simulations	simulation	NOUN	NNS	Number=Plur	8	nsubj:pass	8:nsubj:pass|10:nsubj:xsubj	Entity=abstract-52)
7	were	be	AUX	VBD	Mood=Ind|Number=Plur|Person=3|Tense=Past|VerbForm=Fin	8	aux:pass	8:aux:pass	_
8	used	use	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root	_
9	to	to	PART	TO	_	10	mark	10:mark	Discourse=purpose:71->70
10	understand	understand	VERB	VB	VerbForm=Inf	8	xcomp	8:xcomp	_
11	the	the	DET	DT	Definite=Def|PronType=Art	13	det	13:det	Entity=(abstract-109
12	binding	binding	NOUN	NN	Number=Sing	13	compound	13:compound	Entity=(object-27)
13	poses	pose	NOUN	NNS	Number=Plur	10	obj	10:obj	Entity=abstract-109)
14	and	and	CCONJ	CC	_	16	cc	16:cc	_
15	interacting	interact	VERB	VBG	VerbForm=Ger	16	amod	16:amod	Entity=(substance-110
16	residues	residue	NOUN	NNS	Number=Plur	13	conj	10:obj|13:conj:and	_
17	responsible	responsible	ADJ	JJ	Degree=Pos	13	acl	13:acl	Discourse=elaboration:72->71
18	for	for	ADP	IN	_	20	case	20:case	_
19	inhibitory	inhibitory	ADJ	JJ	Degree=Pos	20	amod	20:amod	Entity=(abstract-104
20	activity	activity	NOUN	NN	Number=Sing	17	obl	17:obl:for	Entity=substance-110)abstract-104)|SpaceAfter=No
21	.	.	PUNCT	.	_	8	punct	8:punct	_

# sent_id = AMALGUM_academic_cyclic-21
# s_type = decl
# text = Also, the stability of water molecules at the binding site of oxytocin was studied using 3D reference interaction site model (3D-RISM) to gain deep insights into the binding of the cyclic peptide at DPP4 druggable region.
1	Also	also	ADV	RB	_	15	advmod	15:advmod	Discourse=joint:73->70|SpaceAfter=No
2	,	,	PUNCT	,	_	1	punct	1:punct	_
3	the	the	DET	DT	Definite=Def|PronType=Art	4	det	4:det	Entity=(abstract-111
4	stability	stability	NOUN	NN	Number=Sing	15	nsubj:pass	15:nsubj:pass|16:nsubj:xsubj	_
5	of	of	ADP	IN	_	7	case	7:case	_
6	water	water	NOUN	NN	Number=Sing	7	compound	7:compound	Entity=(object-112(substance-113)
7	molecules	molecule	NOUN	NNS	Number=Plur	4	nmod	4:nmod:of	Entity=object-112)
8	at	at	ADP	IN	_	11	case	11:case	_
9	the	the	DET	DT	Definite=Def|PronType=Art	11	det	11:det	Entity=(place-114
10	binding	binding	NOUN	NN	Number=Sing	11	compound	11:compound	Entity=(object-27)
11	site	site	NOUN	NN	Number=Sing	4	nmod	4:nmod:at	_
12	of	of	ADP	IN	_	13	case	13:case	_
13	oxytocin	oxytocin	NOUN	NN	Number=Sing	11	nmod	11:nmod:of	Entity=abstract-111)place-114)(substance-100)
14	was	be	AUX	VBD	Mood=Ind|Number=Sing|Person=3|Tense=Past|VerbForm=Fin	15	aux:pass	15:aux:pass	_
15	studied	study	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root	_
16	using	use	VERB	VBG	VerbForm=Ger	15	xcomp	15:xcomp	Discourse=means:74->73
17	3D	3D	NOUN	NN	Number=Sing	18	compound	18:compound	Entity=(abstract-115
18	reference	reference	NOUN	NN	Number=Sing	21	compound	21:compound	_
19	interaction	interaction	NOUN	NN	Number=Sing	20	compound	20:compound	Entity=(place-114(abstract-116)
20	site	site	NOUN	NN	Number=Sing	21	compound	21:compound	Entity=place-114)
21	model	model	NOUN	NN	Number=Sing	16	obj	16:obj	Entity=abstract-115)
22	(	(	PUNCT	-LRB-	_	23	punct	23:punct	Discourse=restatement:75->74|SpaceAfter=No
23	3D-RISM	3D-RISM	PROPN	NNP	Number=Sing	21	appos	21:appos	Entity=(abstract-115)|SpaceAfter=No
24	)	)	PUNCT	-RRB-	_	23	punct	23:punct	_
25	to	to	PART	TO	_	26	mark	26:mark	Discourse=purpose:76->74
26	gain	gain	VERB	VB	VerbForm=Inf	16	advcl	16:advcl:to	_
27	deep	deep	ADJ	JJ	Degree=Pos	28	amod	28:amod	Entity=(abstract-108
28	insights	insight	NOUN	NNS	Number=Plur	26	obj	26:obj	_
29	into	into	ADP	IN	_	31	case	31:case	_
30	the	the	DET	DT	Definite=Def|PronType=Art	31	det	31:det	Entity=(object-27
31	binding	binding	NOUN	NN	Number=Sing	28	nmod	28:nmod:into	_
32	of	of	ADP	IN	_	35	case	35:case	_
33	the	the	DET	DT	Definite=Def|PronType=Art	35	det	35:det	Entity=(substance-43
34	cyclic	cyclic	ADJ	JJ	Degree=Pos	35	amod	35:amod	_
35	peptide	peptide	NOUN	NN	Number=Sing	31	nmod	31:nmod:of	_
36	at	at	ADP	IN	_	39	case	39:case	_
37	DPP4	DPP4	PROPN	NNP	Number=Sing	39	compound	39:compound	Entity=(place-117(abstract-71)
38	druggable	druggable	ADJ	JJ	Degree=Pos	39	amod	39:amod	_
39	region	region	NOUN	NN	Number=Sing	35	nmod	35:nmod:at	Entity=abstract-108)object-27)substance-43)place-117)|SpaceAfter=No
40	.	.	PUNCT	.	_	15	punct	15:punct	_

# sent_id = AMALGUM_academic_cyclic-22
# s_type = decl
# text = Finally, fluorescence assay was used to demonstrate the potential role of oxytocin as a DPP4 inhibitor experimentally.
1	Finally	finally	ADV	RB	Degree=Pos	6	advmod	6:advmod	Discourse=sequence:77->73|SpaceAfter=No
2	,	,	PUNCT	,	_	1	punct	1:punct	_
3	fluorescence	fluorescence	NOUN	NN	Number=Sing	4	compound	4:compound	Entity=(abstract-118(abstract-119)
4	assay	assay	NOUN	NN	Number=Sing	6	nsubj:pass	6:nsubj:pass|8:nsubj:xsubj	Entity=abstract-118)
5	was	be	AUX	VBD	Mood=Ind|Number=Sing|Person=3|Tense=Past|VerbForm=Fin	6	aux:pass	6:aux:pass	_
6	used	use	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root	_
7	to	to	PART	TO	_	8	mark	8:mark	Discourse=purpose:78->77
8	demonstrate	demonstrate	VERB	VB	VerbForm=Inf	6	xcomp	6:xcomp	_
9	the	the	DET	DT	Definite=Def|PronType=Art	11	det	11:det	Entity=(abstract-120
10	potential	potential	ADJ	JJ	Degree=Pos	11	amod	11:amod	_
11	role	role	NOUN	NN	Number=Sing	8	obj	8:obj	_
12	of	of	ADP	IN	_	13	case	13:case	_
13	oxytocin	oxytocin	NOUN	NN	Number=Sing	11	nmod	11:nmod:of	Entity=(substance-100
14	as	as	ADP	IN	_	17	case	17:case	_
15	a	a	DET	DT	Definite=Ind|PronType=Art	17	det	17:det	Entity=(abstract-121
16	DPP4	DPP4	PROPN	NNP	Number=Sing	17	compound	17:compound	Entity=(abstract-71)
17	inhibitor	inhibitor	NOUN	NN	Number=Sing	13	nmod	13:nmod:as	Entity=abstract-120)substance-100)abstract-121)
18	experimentally	experimentally	ADV	RB	Degree=Pos	6	advmod	6:advmod	SpaceAfter=No
19	.	.	PUNCT	.	_	6	punct	6:punct	_

